Connect Biopharma (CNTB) completes rademikibart asthma trial enrollment; expects data September 2026

Connect Biopharma Holdings (CNTB) announced it has completed patient enrollment for its Phase 2 clinical trial of rademikibart (CBP-201) for moderate-to-severe asthma. The trial enrolled 160 patients, with topline data anticipated in September 2026. This milestone advances the company's development pipeline for its IL-4Rα antibody. Rademikibart is an investigational antibody designed to target the interleukin-4 receptor alpha (IL-4Rα), a key mediator in inflammatory diseases. The completion of enrollment keeps the study on track to deliver results later next year. Connect Biopharma previously reported positive Phase 2b data for rademikibart in patients with moderate-to-severe atopic dermatitis, demonstrating its potential across allergic inflammatory conditions.